Some of the mechanisms proposed to drive expression of PD-L1 in tumors include interferon-γ (IFN-γ) produced by tumor infiltrating lymphocytes, genomic alterations, and activation of oncogenic signaling pathways (14–20). This evidence concerns the gene IFNG and neoplasm.